United States Copper Index Fund vs ImmunityBio Inc. Common Stock — how do they compare? United States Copper Index Fund trades at $39.91 (market cap $708.28M), while ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.51B). The key difference: ImmunityBio Inc. Common Stock is far larger — about 14.8× United States Copper Index Fund's market cap, and United States Copper Index Fund is more actively traded (339,046 versus 10,445,785). Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and ImmunityBio Inc. Common Stock for 0 Days on average.
| CPER | IBRX | |
|---|---|---|
Market Cap | $708.28M | $10.51B |
Volume | 339,046 | 10,445,785 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $11.55 |
52-Week Low | $30.27 | $1.98 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $10.97B |
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →